GFAP and Alzheimer disease: In attempts to explain this finding, neurodegenerative biomarkers like neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were measured and found to be higher in COVID-19 patients than non-COVID-19 patients with mild cognitive impairment or AD [71].